Research and Development Expenses Breakdown: Pharming Group N.V. vs Arrowhead Pharmaceuticals, Inc.

Biopharma R&D: Arrowhead vs. Pharming's Decade of Innovation

__timestampArrowhead Pharmaceuticals, Inc.Pharming Group N.V.
Wednesday, January 1, 20142313805014182353
Thursday, January 1, 20155741014715503028
Friday, January 1, 20164145445216183585
Sunday, January 1, 20173169029822382849
Monday, January 1, 20185296850533038206
Tuesday, January 1, 20198104868631777040
Wednesday, January 1, 202012887497941464134
Friday, January 1, 202120634200067178053
Saturday, January 1, 202229730700052531000
Sunday, January 1, 202335318800068914000
Monday, January 1, 2024505870000
Loading chart...

Unlocking the unknown

Unveiling R&D Trends in Biopharmaceuticals: A Comparative Analysis

In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) expenses are a critical indicator of innovation and growth. This analysis delves into the R&D spending patterns of two prominent players: Arrowhead Pharmaceuticals, Inc. and Pharming Group N.V., from 2014 to 2023.

Arrowhead Pharmaceuticals has demonstrated a robust upward trajectory in R&D investments, with a staggering 2,100% increase over the decade, peaking at an estimated $505 million in 2024. This reflects their commitment to pioneering RNA interference therapies. In contrast, Pharming Group N.V. has shown a more modest growth, with R&D expenses increasing by approximately 385% over the same period, reaching around $69 million in 2023.

The data highlights Arrowhead's aggressive expansion strategy, while Pharming's steady growth underscores a more conservative approach. Missing data for 2024 suggests potential shifts in Pharming's strategy, warranting close observation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025